Substance P in human hand veins in vivo: tolerance, efficacy, potency, and mechanism of venodilator action

Clin Pharmacol Ther. 1996 Oct;60(4):435-43. doi: 10.1016/S0009-9236(96)90200-3.

Abstract

Objectives: To study potency, efficacy, development of tolerance, and mechanism of action of substance P, an endothelium-dependent vasodilator neurokinin, in human hand veins in vivo.

Methods: Thirty-three healthy subjects were studied with use of the hand vein compliance technique. In hand veins preconstricted with the alpha 1-agonist phenylephrine, substance P and antagonists of nitric oxide formation (L-NG-mono-methyl-arginine, L-NMMA), adenosine triphosphate (ATP)-dependent potassium channels (glyburide), angiotensin converting enzyme (enalaprilat), and cyclooxygenase (acetylsalicylic acid) were infused and the venodilator effect was measured.

Results: Substance P proved to be the most potent venodilator known thus far (the dose-rate exerting 50% of mean maximum dilation [ED50], geometric mean: 0.105 pmol/min). Rapid development of tolerance occurred in seven of eight volunteers studied. Glyburide decreased the venodilator action of a single dose of substance P (1.5 pmol/min) from 81% to 28% of baseline venodilation (p < 0.05), suggesting that substance P acts through release of endothelium-derived hyperpolarizing factor. The cyclooxygenase-inhibitor acetylsalicylic acid reduced substance P-induced venodilation from 53% +/- 7% to 34% +/- 8% (p < 0.05), whereas L-NMMA had no effect.

Conclusions: Unlike in other vessels, substance P-induced venodilation in hand veins is not mediated through nitric oxide but to a significant extent through a glyburide-sensitive pathway. Therefore it appears likely that substance P activates ATP-dependent potassium channels on vascular smooth muscle cells through the release of endothelium-derived hyperpolarizing factor.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Dose-Response Relationship, Drug
  • Drug Tolerance
  • Female
  • Glyburide / pharmacology
  • Hand
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Male
  • Middle Aged
  • Substance P / antagonists & inhibitors*
  • Substance P / pharmacology*
  • Vasoconstrictor Agents / pharmacology*
  • Vasodilation / drug effects*
  • Veins / drug effects*

Substances

  • Hypoglycemic Agents
  • Vasoconstrictor Agents
  • Substance P
  • Glyburide